14th Course: Advances in Urological Oncology
“Prostate Cancer: from Molecular and Cellular Biology to Therapeutic Advancement”

The Course will be held under the auspices of: • Italian Society of Urological Oncology (SIURO) • University of Palermo • University of Bologna • Faculty of Medicine of the Catholic University of the Sacred Heart of Rome • Italian Ministry of Health • Italian Ministry for Instruction, University and (Scientific) Research • Sicilian Regional Government • World Federation of Scientists

PURPOSE OF THE COURSE

The purpose of the Course is to provide state of the art knowledge and future perspectives on basic and translational research, pathology and advanced therapeutic strategies of prostate cancer in a multidisciplinary approach. Scientific sessions will include interactive discussions between the faculty and the participants. International experts in research and clinical management of prostate cancer will share their views and experience with the audience. The Course is the fourth of a series of courses held under the aegis of the Italian Society of Urological Oncology.

SCIENTIFIC PRELIMINARY PROGRAMME


GENERAL INFORMATION

• Person wishing to attend the Course should write, within December 20” 2012 to: Prof. Michele Pavone-Macaluso c/o E.DI.P.O. s.r.l. Via Libertà, 103 - Palermo - fax +39 091 6251719 - michpav@tin.it - edi.po@tiscali.it, specifying: • date and place of birth, together with present nationality • degree and other academic qualifications • present position and place of work, address and e-mail.

• Accreditation for Continuing Medical Education (by the Italian Ministry of Health (ECM: Educazione Continua in Medicina) will be applied.

• The registration fee for participants € 2.200,00 plus VAT, to be paid within February 10”, 2013 to the Organising Secretariat – is inclusive of: scientific session, transfer from airport (Palermo or Trapani) to Erice and viceversa, lodging on full board basis and social events.

• Payment by bank draft (bank fees at your charge)
Bank: Unicredit, Ag. 7 – Palermo
IBAN: IT 66 X 02008 04696 000300353901
Swift Code (BIC): UNCRITM153
Beneficiary: E.DI.P.O. s.r.l.
Via Libertà, 103 – 90143 Palermo.

EMFSC PRESIDENT AND DIRECTOR OF THE CENTRE
Antonino Zichichi

DIRECTOR OF THE SCHOOL
Michele Pavone-Macaluso

DIRECTORS OF THE COURSE
Giario Natale Conti
Como, Italy
Gigliola Sica
Roma, Italy

SCIENTIFIC SECRETARIAT
Alessandro Bertacchini – Bologna, Italy
Enrico Bolliot – Orbassano (TO), Italy
Sergio Bracarda – Areezo, Italy
Fortunata Lacopino – Roma, Italy
Giovanni Luigi Pappagallo – Mirano (VE) – Italy
Carlo Pavone – Palermo, Italy
Vittorio Vavassori – Bergamo, Italy
email: slacavera@libero.it

ORGANISING SECRETARIAT
E.DI.P.O. s.r.l. Serenella La Caverna
Via Libertà, 103 – 90143 - Palermo (Italy)
Tel/Fax: +39.091.625719
email: edi.po@tiscali.it - slacavera@libero.it

Erice, Sicily - Italy  April 16-21, 2013
Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication (print and online) of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÉ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (Cardiff, UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEENE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZELLO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
Contents continued


Distance to the Neurooncological Center: A Negative Prognostic Factor in Patients with Glioblastoma Multiforme. An Epidemiological Study. J. KERSCHBAUMER, C.F. FREYSCHLAG, R. BAUER, A.A. OBWEGESER, G.A. SCHUBERT, C. THOMÉ, M. SEIZ (Innsbruck; Feldkirch, Austria) ...................... 5515

Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. T. YANAI, S. IWASA, H. HASHIMOTO, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA, H. YAMAMOTO (Tokyo, Japan) ....................................................................................... 5521


Book Reviews ........................................................................................................................................ 5535

Announcements .................................................................................................................................... 5541

Index .................................................................................................................................................. 5543

Review (page 5139)
Effect of Menatetrenone, a Vitamin K\textsubscript{2} Analog, on Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Prospective Randomized Controlled Trial. M. ISHIZUKA, K. KUBOTA, M. SHIMODA, J. KITA, M. KATO, K.H. PARK, T. SHIRAKI (Tochigi, Japan) ............................................................ 5415


Low-grade Central Osteosarcoma of the Metatarsal Bone: A Clinicopathological, Immunohistochemical, Cytogenetic and Molecular Cytogenetic Analysis. J. NISHIO, H. IWASAKI, S. TAKAGI, H. SEO, M. AOKI, K. NABESHIMA, M. NAITO (Fukuoka, Japan) .................................................................... 5429


Prognostic Value of Serum CA9 in Patients with Metastatic Clear Cell Renal Cell Carcinoma under Targeted Therapy. M. GIGANTE, G. LI, C. FERALY, D. PEROL, E. BLANC, S. PAUL, A. ZHAO, J. TOSTAIN, B. ESCUDIER, S. NEGRIER, C. GENIN (Saint-Etienne; Lyon; Villejuif, France).................................................. 5447

Treatment of Hepatic Metastases from Gastric or Gastroesophageal Adenocarcinoma with Computed Tomography-guided High-dose-rate Brachytherapy (CT-HDRBT). D. GEISEL, T. DENECKE, F. COLLETTINI, C. GRIESER, P. WUST, P. THUSS-PATIENCE, B. HAMM, G. GEBAUER (Berlin, Germany).................... 5453


Adverse Pathological Findings in Needle Biopsy Gleason Score 6 Prostate Cancers with Low and Intermediate Preoperative PSA Levels Following Radical Prostatectomy. I. HEIDEGGER, M. LADURNER, V. SKRADSCHI, H. KLOCKER, G. SCHÄFER, W. HORNINGER, J. BEKTIC (Innsbruck, Austria)....... 5481

Hepatic Arterial Infusion of Irinotecan, 5-Fluorouracil and Leucovorin in Patients with Liver Metastases from Colorectal Carcinoma. B. MELICHAR, Z. VOBOŘIL, A. KRAJINA, E. MALNÍŘOVA, P. WEINER, M. NOVÁ, A. RYŠKA, J. DVÓRAK (Olomouc; Hradec Králové; Jindřichův Hradec, Czech Republic) ........... 5487

Comparison of Prognostic Value of In Vitro Drug Resistance and Bone Marrow Residual Disease on Day 15 of Therapy in Childhood Acute Lymphoblastic Leukemia. J. STYCZYSKI, M. PIATKOWSKA, A. JAWORSKA-POSADZY, K. Czyzewski, M. KUBICKA, B. KOLODZIEJ, B. KURYLO-RAFINSKA, R. DEBSKI, M. POGORZALA, M. WYSOCKI (Bydgoszcz, Poland) .......................................................... 5495

Contents continued on the preceding page

Intratumoral $^{224}$Ra-Loaded Wires Spread Alpha-Emitters Inside Solid Human Tumors in Athymic Mice Achieving Tumor Control. T. COOKS, M. TAL, S. RAAB, M. EFRATI, S. REITKOPF, E. LAZAROV, R. ETZYONI, M. SCHMIDT, L. ARAZI, I. KELSON, Y. KEISARI (Tel Aviv, Israel) .......................................................... 5315

Effects of Bicalutamide and 4OH-Tamoxifen on Androgen-regulated Gene Expression in the LNCaP Cell Line. R. MANGERINI, F. ARGELLATI, U. PFEEFFER, F. BOCCARDO (Genoa, Italy) .......................................................... 5323

Studies on the Activity of Two Trans-Planaramine Platinum(II) Complexes Coded as DH4 and DH5 in Human Ovarian Tumour Models. N. DEQNAH, J.Q. YU, P. BEALE, F. HUQ (Sydney; Concord, NSW, Australia) ..................................................................................................................... 5331

Curcumin Resistance Induced by Hypoxia in HepG2 Cells Is Mediated by Multidrug-resistance-associated Proteins. T. SAKULTERDKIAT, C. SRISOMSAP, R. UDOMSANGPETCH, J. SVASTI, K. LIRDPRAPAMONGKOL (Bangkok, Thailand) ..................................................................................................................... 5337

Artonin E Mediates MCL1 Down-regulation and Sensitizes Lung Cancer Cells to Anoikis. E. WONGPANKAM, P. CHUNHACHA, V. PONGRAKHANANON, B. SRTULARAK, P. CHANVORACHOTE (Bangkok, Thailand) ..................................................................................................................... 5343

Induction of Apoptosis of SW480 Human Colon Cancer Cells by (−)-Epicatechin Isolated from Bulnesia sarmienti. D. KIM, M.L. MOLLAH, K. KIM (Daegu, Republic of Korea; Selangor, Malaysia) ............... 5353

Suppressive Effects of Cyclophosphamide and Gemcitabine on Regulatory T-Cell Induction In Vitro. S. KAN, S. HAZAMA, K. MAEDA, Y. INOUE, S. HOMMA, S. KOIDO, M. OKAMOTO, M. OKA (Yamaguchi; Tokyo, Japan) ........................................................................................................................................... 5363

Antiproliferative, Antioxidant and Anti-inflammatory Effects of Hydroxytyrosol on Human Hepatoma HepG2 and Hep3B Cell Lines. V. TUTINO, M.G. CARUSO, C. MESSA, E. PERRI, M. NOTARNICOLA (Bari; Rende, Italy) .................................................................................................................................................. 5371

Gut Fermentation Products of Inulin-type Fructans Modulate the Expression of Xenobiotic-metabolising Enzymes in Human Colonic Tumour Cells. U. MUNJAL, D. SCHARLAU, M. GLEI (Jena, Germany) .... 5379

Quantification of Breast Cancer Cells in Peripheral Blood Samples by Real-Time RT-PCR. M. ZEBISCH, A.C. KÖBLI, C. SCHINDLBECK, J. NEUGEBAUER, S. HEUBLEIN, M. ILMER, B. RACK, K. FRIESE, U. JESCHKE, U. ANDERGASSEN (Munich; Traunstein, Germany; Houston, TX, USA) .......... 5387

Clinical Studies

Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Mesothelioma (MPM). G. PASELLO, G. MARULLI, V. POLO, C. BREDA, L. BONANNO, L. LOREGGIANI, F. REA, A. FAVARETTO (Padua, Italy) ........................................................................................................................................... 5393

Phase I Study of Combination Chemotherapy Consisting of Paclitaxel, Cisplatin, and S-1 in Patients with Unresectable Gastric Cancer (KOGC-02). T. TAKASHI, Y. SAIKAWA, K. FUKUDA, S. FUNAKOSHI, H. KAWAKUBO, H. TAKEUCHI, H. TAKAISHI, Y. KITAGAWA (Tokyo, Japan) ................. 5401

Evaluation of 5-FU Plasma Concentration by $^{13}$C Breath Test in Patients Treated with Oral 5-FU Analogs. M. HIGASHIDA, H. MATSUMOTO, H. KUBOTA, H. MURAKAMI, Y. KAWABE, H. NAKASHIMA, Y. OKA, H. OKUMURA, M. NAKAMURA, T. HIRAI (Okayama, Japan) ..................................................................................................................... 5407

Contents continued on the preceding page
Bevacizumab Impairs Hepatocyte Proliferation after Partial Hepatectomy in a Rabbit Model. A. DUPRE, A. PARADISI, S. LANGONNET, A. GANDINI, P. MEHLEN, M. RIVOIRE (Lyon, France) ................................. 5193

Recognition of a Natural WT1 Epitope by a Modified WT1 Peptide-specific T-Cell Receptor. T. TAMANAKA, Y. OKA, F. FUJIKI, A. TSUBOI, A. KATSUHARA, H. NAKAJIMA, N. HOSEN, S. NISHIDA, Y.-H. LIN, S. TACHINO, Y. AKATSUKA, K. KUZUSHIMA, Y. OJI, A. KUMANOGOH, H. SUGIYAMA (Osaka; Toyoake; Nagoya, Japan) ...................................................................................................................... 5201

Overexpression of CD9 in Human Breast Cancer Cells Promotes the Development of Bone Metastases. P. KISCHEL, A. BELLAHCENE, B. DEUX, V. LAMOUR, R. DOBSON, E. DE PAUW, P. CLEZARDIN, V. CASTRONOVO (Liège, Belgium; Lyon, France) ............................................................................ 5211

Computer-assisted Diagnosis (CAD) in Colposcopy: Evaluation of a Pilot Study. G. MEHLHORN, A. KAGE, C. MÜNZENMAYER, M. BENZ, M.C. KOCH, M.W. BECKMANN, T. WITTMENBERG (Erlangen, Germany) ............................................................................................................. 5221

Immunohistochemical Expression and Prognostic Significance of HIF-1α and VEGF-C in Neuroendocrine Breast Cancer. I. MARTON, F. KNEŽEVIĆ, S. RAMIĆ, M. MILOŠEVIĆ, D. TOMAS (Zagreb, Croatia) ................................................. 5227

Macrophage Migration-inhibitory Factor Levels in Serum of Patients with Ovarian Cancer Correlates with Poor Prognosis. M. KROCKENBERGER, P. KRANKE, S. HÄUSLER, J.B. ENGEL, E. HORN, K. NÜRNBERGER, J. WISCHHUSEN, J. DIETL, A. HÖNIG (Würzburg; Regensburg, Germany) ................................................................. 5233

Relationship between Structure and Antiproliferative Activity of Polymethoxylavones towards HL60 Cells. S. KAWAI, T. IKUINA, T. HIKIMA, T. TOKIWANO, Y. YOSHIZAWA (Saitama; Akita, Japan) ........................................ 5239

Expression of E-Cadherin and α-Catenin in T1 N0 Laryngeal Cancer. E. CARICO, M. RADICI, N.S. LOSITO, S. RAFFA, L. FIRRISI, A. FABIANO, M. MANOLA, A.VECCHIONE, M.R. GIOVAGNOLO (Rome; Naples, Italy) ... 5245

Gefitinib and Gemcitabine Coordinately Inhibited the Proliferation of Cholangiocarcinoma Cells. Y. NAKAJIMA, H. TAKAGI, S. KAKIZAKI, N. HORIGUCHI, K. SATO, N. SUNAGA, M. MORI (Gunma, Japan) ........................................................................................................................................... 5251

Antitumoral Efficacy of Four Histone Deacetylase Inhibitors in Hepatoma In Vitro and In Vivo. M. GANSLMAYER, P. KONTUREK, C. HEROLD, M.F. NEURATH, S. ZOPF (Erlangen; Saalfeld, Germany) .................................................................................................................................................. 5263

Effects of Structural Modifications of Daunorubicin on In Vitro Antileukemic Activity. M. STOJAK, L. MAZUR, M. OPYDO-CHANEK, M. ŁUKAWSKA, I. OSZCZAPOWICZ (Cracow; Warsaw, Poland) ........................................................................................................ 5271

Effects of Voltage-gated K+ Channel Blockers in Gefitinib-resistant H460 Non-small Cell Lung Cancer Cells. W.I. JEON, P.D. RYU, S.Y. LEE (Seoul, South Korea) ................................................................................................................ 5279


Therapeutic Radiation Induces Different Changes in Expression Profiles of Metallothionein (MT) mRNA, MT Protein, Ki 67 and Minichromosome Maintenance Protein 3 in Human Rectal Adenocarcinoma. J. SZELACHOWSKA, P. DZIEGIEL, R. TARKOWSKI, A. GOMULKIEWICZ, M. BEBENEK, A. HALON, K. FORTUNA, A. WOJNAR, J. KORNAFEL, R. MATKOWSKI (Wrocław, Poland) ........................................................................................................ 5291

Expression of mRNAs of Urocortin and Corticotropin-releasing Factor Receptors in Malignant Glioma Cell Lines. M. KAMADA, K. IKEDA, K. FUJIJOKA, N. AKIYAMA, K. AKIYOSHI, Y. INOUE, S. HANADA, K. YAMAMOTO, K. TOJO, Y. MANOME (Tokyo, Japan) ........................................................................................................ 5299

Contents continued on the preceding page